Develops therapies for dermatological conditions.
Dermata Therapeutics, Inc., headquartered in San Diego, California, is a clinical-stage biotechnology company dedicated to the identification, development, and commercialization of pharmaceutical products targeting both medical and aesthetic skin conditions. At the forefront of its research efforts is DMT310, the company's leading product candidate. DMT310 has successfully completed a Phase IIb clinical trial for the treatment of moderate-to-severe acne and has also undergone Phase Ib proof of concept trials for Mild-to-Moderate Psoriasis. Currently, it is advancing through a Phase 2 clinical trial for the treatment of moderate-to-severe rosacea, demonstrating Dermata Therapeutics' commitment to addressing a spectrum of dermatological needs.
In addition to DMT310, Dermata Therapeutics is actively developing DMT410, which has completed Phase Ib proof of concept trials targeting hyperhidrosis (excessive sweating) and various aesthetic conditions. The company's innovative approach combines scientific rigor with a focus on enhancing quality of life through advanced dermatological solutions. Founded in 2014, Dermata Therapeutics has rapidly established itself as a key player in the biotechnology sector, leveraging its expertise to bring novel treatments to market.
With its strategic location in San Diego, a hub renowned for biotechnological innovation, Dermata Therapeutics benefits from proximity to world-class research institutions and talent. The company continues to expand its pipeline and explore new therapeutic avenues, aiming to set new standards in dermatological care and improve patient outcomes globally.